"It shows a chart that has made the transition from bearishness to bullishness. The price per share has broken through and is holding above both the 50 and 200 day moving averages with a “Golden Cross” of the 50 and 200 dma’s looking imminent. The indicators continue to hold bullish positions signaling strength of momentum and trend with no strong negative divergences. Support is at $10 and $11 with resistance at $12."
Ventrus Biosciences is a development stage pharmaceutical company focused on the development of late-stage prescription drugs for gastrointestinal disorders. The company’s lead products are: Iferanserin (VEN 309) for the topical treatment of hemorrhoids, for which the first Phase 3 clinical trial began in August 2011 and is ongoing, and topical diltiazem (VEN 307) for the treatment of anal fissures for which the first Phase 3 trial was initiated in November 2010, and is ongoing. Ventrus’ product candidate portfolio also includes topical phenylephrine (VEN 308) intended to treat fecal incontinence. VEN 307 and VEN 308 are two molecules that were previously approved and marketed for other indications and that have been formulated into the company’s in-licensed proprietary topical treatments for these new gastrointestinal indications. VEN 309 is a New Chemical Entity (NCE).